Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. - Wikidata - awgldk - TriplyDB

Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy.

Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy.

http://www.wikidata.org/entity/Q44738460

about

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil Rolling circle amplification, a powerful tool for genetic and functional studies of complete hepatitis B virus genomes from low-level infections and for directly probing covalently closed circular DNA.Hepatitis B virus genetic mutations and evolution in liver diseases.Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance.Mutations associated with occult hepatitis B in HIV-positive South Africans Quantifying anti-HBV effect of targeted ribonuclease by real-time fluorescent PCR.Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance.Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay.Analysis of hepatitis B virus genotype changes in patients with chronic hepatitis B infection on tenofovir therapy.COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma.Role of hepatitis B virus, hepatitis D virus and other determinants on suppression of hepatitis C viraemia in HIV infected patients with chronic HCV infection: a longitudinal evaluation.Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants

P2860

Q33233245-56549588-42D6-4170-A99A-837136687B9F Q33349693-9FB983D2-3AA8-4A47-8727-4620C31611B7 Q33594925-736146B6-EA13-4583-B155-168681040913 Q34382067-1AB385BA-8347-4F56-9CAA-F887B66D29E4 Q36035578-6A1EF73F-6542-49A7-B270-C6DDA7E2621D Q36065628-52A7DD18-357B-4E59-B24A-23C95B5945BE Q37470263-34E469F3-88B5-48FC-86C8-964CBFA0D351 Q40404341-0C75BEEE-3B2F-40A1-AA3E-08838F1303E6 Q40799373-97F87D10-F03E-4882-8973-B68899B5241F Q41824086-84EC2BB5-577D-416F-B620-D82A7E4683B1 Q45392641-62A347D3-95E2-417F-9ABB-5CF3517F4242 Q57205383-4D4FF0A9-3233-4367-B09B-D543C1B27F71

P2860

Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy.

http://www.wikidata.org/entity/Q44738460

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Evolution of hepatitis B viral ...... ng adefovir dipivoxil therapy.

@en

Evolution of hepatitis B viral ...... ng adefovir dipivoxil therapy.

@nl

type

label

Evolution of hepatitis B viral ...... ng adefovir dipivoxil therapy.

@en

Evolution of hepatitis B viral ...... ng adefovir dipivoxil therapy.

@nl

prefLabel

Evolution of hepatitis B viral ...... ng adefovir dipivoxil therapy.

@en

Evolution of hepatitis B viral ...... ng adefovir dipivoxil therapy.

@nl

P1433

Q44738460-6975DC45-28EF-4C63-AD03-F7F0BF86F02E

P1476

Q44738460-2B40277C-5E20-4B74-B14C-631A243632A9

P2093

Q44738460-0758929F-B9E6-4680-8098-C66034A5529B

Q44738460-4498B7F6-7638-4EDD-AE69-F4C58EEE999B

Q44738460-624E9D1C-088F-45D6-B8B0-0C87B53BE320

Q44738460-7F7B202C-577C-4B00-92D5-95D40F4ACD6D

Q44738460-B4E010C0-BC74-4170-9BDE-124F5D94B61A

Q44738460-F6F30656-1E28-4215-B95A-E8C11005D58D

P2860

Q44738460-05D29142-C9B4-4E06-9EAB-392049303228

Q44738460-08313904-F2A4-42C5-9168-9A53BFBA2071

Q44738460-1C60A755-7D7A-4671-9A8F-293B779BB8A6

Q44738460-1EE85ED0-5500-499D-A0D1-85D4986D102A

Q44738460-26E68201-3FAA-4295-AB75-42E4D2F79CE2

Q44738460-27B9914F-DD3A-4AB1-9103-EAABEF4D68B9

Q44738460-29D37C0F-B7F3-4D48-9E09-2DA00F7A34C1

Q44738460-46ECD954-5F73-4F1A-B0BC-5073AA803473

Q44738460-489C9450-8256-4FDB-A6AB-513702D48F0B

Q44738460-5369F0DB-A5DB-4D1B-8279-6F4D7782F635

P304

Q44738460-6AC8B3AF-980E-442A-9C08-D3D335BD994A

P31

Q44738460-ED1F8A72-B2B6-4494-BD5C-F12F3D7ED039

P356

Q44738460-C86AA083-441E-4759-BEA9-86C5CC26F7F8

P433

Q44738460-FBE55EF9-1FE0-456F-9451-049B73D4BAA8

P478

Q44738460-77EB18E3-6147-4EFD-8D53-4948E88796BB

P50

Q44738460-4AA82C48-C269-46BD-855F-1C6313C8E198

P577

Q44738460-FB29948C-0595-440B-AF4E-9FD0EC22BB55

P698

Q44738460-F43D8AAB-EDB4-4ECC-B2AB-D2A80271E39D

P921

Q44738460-A01C709C-E30B-4233-8C08-3F3D596050FE

P356

J.1365-2893.2003.00471.X

P1433

Journal of Viral Hepatitis

P1476

Evolution of hepatitis B viral ...... ing adefovir dipivoxil therapy

@en

P2093

B Werle

http://www.w3.org/2001/XMLSchema#string

C Trépo

http://www.w3.org/2001/XMLSchema#string

K Cinquin

http://www.w3.org/2001/XMLSchema#string

M Maynard

http://www.w3.org/2001/XMLSchema#string

P Marcellin

http://www.w3.org/2001/XMLSchema#string

S Pol

http://www.w3.org/2001/XMLSchema#string

P2860

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus

Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture

Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo.

Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks

Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.

Viral dynamics in hepatitis B virus infection.

Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection.

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

P304

74-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2893.2003.00471.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14738561

http://www.w3.org/2001/XMLSchema#string

P921